SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.

Financials Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Equities

002603

CNE1000015S0

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
19.58 ^CNY	+0.67%		+1.40%	-15.13%

Apr. 26	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 26	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Valuation

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Capitalization ¹	14,801	30,365	32,746	50,054	38,543	32,712	-
Enterprise Value (EV) ¹	14,801	30,365	32,746	49,007	39,009	30,366	29,257
P/E ratio	24.9 x	25 x	24.4 x	21.2 x	28.5 x	13.6 x	11.8 x
Yield	1.61%	3.92%	1.53%	1.67%	1.3%	2.55%	2.79%
Capitalization / Revenue	2.54 x	3.46 x	3.24 x	3.99 x	3.74 x	2.53 x	2.21 x
EV / Revenue	2.54 x	3.46 x	3.24 x	3.91 x	3.78 x	2.35 x	1.97 x
EV / EBITDA	15.2 x	17.7 x	16.9 x	15 x	16.8 x	7.31 x	6.15 x
EV / FCF	-	68,745,950 x	-	-	-	-	-
FCF Yield	-	0%	-	-	-	-	-
Price to Book	1.88 x	3.44 x	3.61 x	4.58 x	3.37 x	2.32 x	2.02 x
Nbr of stocks (in thousands)	1,667,081	1,667,081	1,670,705	1,670,705	1,670,705	1,670,705	-
Reference price ²	8.879	18.21	19.60	29.96	23.07	19.58	19.58
Announcement Date	2/27/20	2/25/21	4/28/22	4/25/23	4/26/24	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Net sales ¹	5,825	8,782	10,117	12,533	10,318	12,915	14,828
EBITDA ¹	973.9	1,713	1,939	3,271	2,321	4,151	4,756
EBIT ¹	710.2	1,438	1,569	2,830	1,780	2,915	3,410
Operating Margin	12.19%	16.37%	15.51%	22.58%	17.25%	22.57%	23%
Earnings before Tax (EBT) ¹	707.9	1,422	1,554	2,781	1,684	2,815	3,241
Net income ¹	606.5	1,219	1,344	2,362	1,352	2,411	2,779
Net margin	10.41%	13.88%	13.28%	18.84%	13.11%	18.67%	18.74%
EPS ²	0.3571	0.7286	0.8044	1.414	0.8095	1.445	1.664
Free Cash Flow	-	441.7	-	-	-	-	-
FCF margin	-	5.03%	-	-	-	-	-
FCF Conversion (EBITDA)	-	25.79%	-	-	-	-	-
FCF Conversion (Net income)	-	36.24%	-	-	-	-	-
Dividend per Share ²	0.1429	0.7143	0.3000	0.5000	0.3000	0.5000	0.5467
Announcement Date	2/27/20	2/25/21	4/28/22	4/25/23	4/26/24	-	-

¹CNY in Million²CNY

Estimates

Balance Sheet Analysis

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Net Debt ¹	-	-	-	-	466	-	-
Net Cash position ¹	-	-	-	1,048	-	2,346	3,455
Leverage (Debt/EBITDA)	-	-	-	-	0.2005 x	-	-
Free Cash Flow	-	442	-	-	-	-	-
ROE (net income / shareholders' equity)	7.83%	14.5%	14.9%	23.6%	12.2%	17.2%	17.3%
ROA (Net income/ Total Assets)	6.88%	11.9%	11%	15.9%	-	13.5%	13.8%
Assets ¹	8,813	10,281	12,199	14,864	-	17,907	20,070
Book Value Per Share ²	4.710	5.290	5.430	6.540	6.850	8.450	9.710
Cash Flow per Share ²	0.0400	0.9400	0.3200	2.090	0.0900	1.870	2.170
Capex ¹	454	1,144	672	214	310	1,090	1,277
Capex / Sales	7.8%	13.03%	6.65%	1.7%	3%	8.44%	8.61%
Announcement Date	2/27/20	2/25/21	4/28/22	4/25/23	4/26/24	-	-

¹CNY in Million²CNY

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.58 CNY

Average target price

24.16 CNY

Spread / Average Target

+23.39%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.51B
DONG-E-E-JIAO CO.,LTD.	+35.04%	5.92B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.97B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+33.40%	1.38B

Alternative Medicine